|
Jul 30
|
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Jul 30
|
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
|
|
Jul 29
|
Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know
|
|
Jul 10
|
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains?
|
|
Jun 27
|
3 Promising Genomics Stocks to Keep an Eye On in 2025
|
|
Jun 17
|
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
|
|
Jun 13
|
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
|
|
Jun 5
|
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?
|
|
Jun 4
|
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
|
|
Jun 3
|
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
|
|
Apr 25
|
Beam Therapeutics to Report Q1 Earnings: What's in the Cards?
|
|
Apr 21
|
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
|
|
Mar 14
|
Biotech Alert: Searches spiking for these stocks today
|
|
Mar 11
|
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
|
|
Mar 10
|
Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now?
|
|
Mar 10
|
Beam Therapeutics Says Initial Data Show BEAM-302 Increases Alpha-1 Antitrypsin Protein
|
|
Mar 10
|
Beam Therapeutics Announces Pricing of Underwritten Offering
|
|
Mar 10
|
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
|
|
Feb 24
|
Cathie Wood buys $11 million of under-the-radar AI stock
|
|
Feb 24
|
Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences
|